Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:35 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532983 | NSE: RPGLIFE

RPG Life Sciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹2,044.51Fairly Valued by 8.87%vs CMP ₹1,878.00

P/E (29.6) × ROE (25.5%) × BV (₹335.00) × DY (1.07%)

₹1,372.71Overvalued by 26.91%vs CMP ₹1,878.00
MoS: -36.8% (Negative)Confidence: 61/100 (Moderate)Models: 2 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹2,688.9821%Under (+43.2%)
Graham NumberEarnings₹960.9515%Over (-48.8%)
Earnings PowerEarnings₹506.5510%Over (-73%)
DCFCash Flow₹3,012.3410%Under (+60.4%)
Net Asset ValueAssets₹335.087%Over (-82.2%)
EV/EBITDAEnterprise₹1,100.798%Over (-41.4%)
Dividend DiscountDividends₹396.008%Over (-78.9%)
Earnings YieldEarnings₹1,225.107%Over (-34.8%)
ROCE CapitalReturns₹678.538%Over (-63.9%)
Revenue MultipleRevenue₹394.955%Over (-79%)
Consensus (10 models)₹1,372.71100%Overvalued
Key Drivers: EPS CAGR 31.5% lifts DCF — verify sustainability. | Wide model spread (₹335–₹3,012) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 31.5%

*Investments are subject to market risks

Investment Snapshot

78
RPG Life Sciences Ltd scores 78/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health92/100 · Strong
ROCE 32.8% ExcellentROE 25.5% ExcellentD/E 0.01 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money65/100 · Strong
FII holding stable No changeDII holding up 0.90% MF buyingPromoter holding at 73.0% Stable
Earnings Quality65/100 · Strong
OPM expanding (20% → 24%) Improving
Quarterly Momentum70/100 · Strong
Revenue (4Q): +6% YoY GrowingProfit (4Q): +156% YoY StrongOPM: 22.0% (down 6.0% YoY) Margin pressure
Industry Rank90/100 · Strong
P/E 29.6 vs industry 53.8 Cheaper than peersROCE 32.8% vs industry 16.4% Above peersROE 25.5% vs industry 15.2% Above peers3Y sales CAGR: 14% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:35 am

Market Cap 3,105 Cr.
Current Price 1,878
Intrinsic Value₹1,372.71
High / Low 2,725/1,731
Stock P/E29.6
Book Value 335
Dividend Yield1.07 %
ROCE32.8 %
ROE25.5 %
Face Value 8.00
PEG Ratio0.94

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for RPG Life Sciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
RPG Life Sciences Ltd 3,105 Cr. 1,878 2,725/1,73129.6 3351.07 %32.8 %25.5 % 8.00
Aarti Drugs Limited 3,162 Cr. 346 575/31217.0 1470.58 %13.5 %13.0 % 10.0
Advanced Enzyme Technologies Ltd 2,981 Cr. 266 367/25220.7 1331.95 %13.1 %9.54 % 2.00
Gufic BioSciences Ltd 2,895 Cr. 289 409/26857.3 62.70.03 %13.2 %12.3 % 1.00
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of RPG Life Sciences Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 131118148154154127165172173143169182180
Expenses 101103116116116106126126124118133143140
Operating Profit 29163237382139464925353940
OPM % 22%13%22%24%25%16%24%27%28%18%21%21%22%
Other Income 1222222-253115516-5
Interest 0000000000000
Depreciation 4444445555555
Profit before tax 261430353618361547135354929
Tax % 26%25%26%26%26%25%26%72%26%13%26%25%24%
Net Profit 19102226261327435117263722
EPS in Rs 11.556.2613.3615.6416.008.0116.182.5421.1270.9515.9022.2813.38

Last Updated: February 4, 2026, 9:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 3:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 236242279294344330376389440513582653674
Expenses 224228256274306296315318353408453493534
Operating Profit 121423203834607187104129161140
OPM % 5%6%8%7%11%10%16%18%20%20%22%25%21%
Other Income 66111811-5134795131
Interest 3324553211121
Depreciation 11111011141516161616172121
Profit before tax 6511223201536547392118233249
Tax % 18%0%0%10%34%28%20%25%30%26%26%21%
Net Profit 531122113112940516888183203
EPS in Rs 32.290.607.0312.708.136.5417.5424.1931.1340.9053.00110.79122.51
Dividend Payout % 6%132%23%22%30%37%23%30%31%29%30%22%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-98.11%1100.00%75.00%-38.10%-15.38%163.64%37.93%27.50%33.33%29.41%107.95%
Change in YoY Net Profit Growth (%)0.00%1198.11%-1025.00%-113.10%22.71%179.02%-125.71%-10.43%5.83%-3.92%78.54%

RPG Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:10%
5 Years:12%
3 Years:14%
TTM:10%
Compounded Profit Growth
10 Years:63%
5 Years:29%
3 Years:31%
TTM:12%
Stock Price CAGR
10 Years:32%
5 Years:46%
3 Years:46%
1 Year:6%
Return on Equity
10 Years:20%
5 Years:24%
3 Years:25%
Last Year:26%

Last Updated: September 5, 2025, 1:10 pm

Balance Sheet

Last Updated: February 1, 2026, 1:49 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 13131313131313131313131313
Reserves 113112120134142147163203243294362517541
Borrowings 15332345543612210000
Other Liabilities 563949558254788588112138127152
Total Liabilities 196197205247291251267303345419513658706
Fixed Assets 106105109137131128123113104124114172179
CWIP 112291710123125961627
Investments 000000000589112793
Other Assets 899294108152106134178210211212343407
Total Assets 196197205247291251267303345419513658706

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -6-23371546505865919478
Cash from Investing Activity + 59-10-15-30-16-19-11-8-35-106-79-42
Cash from Financing Activity + -5412-18230-26-39-10-14-17-20-27
Net Cash Flow 0-0-01-1004017-32-59
Free Cash Flow 51-1218-48-1263950415825151
CFO/OP 44%14%150%58%48%144%94%94%96%111%96%81%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-3.00-19.000.00-25.00-16.00-2.0048.0069.0086.00104.00129.00161.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 566148497243625427273148
Inventory Days 180149156163171136133162214203200159
Days Payable 17610913510216583127132117138140135
Cash Conversion Cycle 601017011078966884124919072
Working Capital Days 302726202220415247332545
ROCE %2%2%9%10%13%10%23%27%31%33%35%33%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 72.82%72.82%72.82%72.82%72.82%72.82%72.82%72.95%72.95%72.95%72.95%72.95%
FIIs 0.38%0.33%0.46%0.56%0.90%1.15%1.35%1.30%1.46%1.35%1.11%1.00%
DIIs 0.11%0.27%1.57%1.77%2.16%2.61%5.45%6.06%6.14%6.49%6.70%7.04%
Public 26.70%26.58%25.15%24.85%24.12%23.44%20.40%19.70%19.46%19.22%19.23%19.01%
No. of Shareholders 20,83720,22621,08821,86622,13722,23223,48124,89124,86725,83226,65725,905

Shareholding Pattern Chart

No. of Shareholders

RPG Life Sciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Multi Cap Fund 176,287 0.43 39.39N/AN/AN/A
Union Small Cap Fund 55,596 0.73 12.42N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 8.008.008.008.008.00
Basic EPS (Rs.) 110.8053.0140.9031.1324.19
Diluted EPS (Rs.) 110.8053.0140.9031.1324.19
Cash EPS (Rs.) 123.7663.3350.2740.6034.15
Book Value[Excl.RevalReserv]/Share (Rs.) 320.80226.67186.00154.66130.88
Book Value[Incl.RevalReserv]/Share (Rs.) 320.80226.67186.00154.66130.88
Dividend / Share (Rs.) 24.0016.0012.009.607.20
Revenue From Operations / Share (Rs.) 395.12351.96310.09266.16235.31
PBDIT / Share (Rs.) 104.2081.8565.0054.0342.84
PBIT / Share (Rs.) 91.2571.5355.6244.5632.88
PBT / Share (Rs.) 140.8271.2655.4444.2432.40
Net Profit / Share (Rs.) 110.8053.0140.9031.1324.19
PBDIT Margin (%) 26.3723.2520.9620.2918.20
PBIT Margin (%) 23.0920.3217.9316.7413.97
PBT Margin (%) 35.6320.2417.8716.6213.76
Net Profit Margin (%) 28.0415.0613.1911.6910.27
Return on Networth / Equity (%) 34.5323.3821.9820.1218.48
Return on Capital Employeed (%) 28.0430.9729.0527.8624.30
Return On Assets (%) 27.8517.0916.1214.9313.18
Total Debt / Equity (X) 0.000.000.000.000.01
Asset Turnover Ratio (%) 1.121.251.341.361.37
Current Ratio (X) 3.882.282.572.582.21
Quick Ratio (X) 3.111.501.641.551.47
Inventory Turnover Ratio (X) 6.741.230.961.251.63
Dividend Payout Ratio (NP) (%) 14.4422.6423.4723.130.00
Dividend Payout Ratio (CP) (%) 12.9218.9519.1017.730.00
Earning Retention Ratio (%) 85.5677.3676.5376.870.00
Cash Earning Retention Ratio (%) 87.0881.0580.9082.270.00
Interest Coverage Ratio (X) 277.95300.80346.74171.8389.67
Interest Coverage Ratio (Post Tax) (X) 163.32195.80219.19100.0051.63
Enterprise Value (Cr.) 3626.892494.101093.81855.55600.68
EV / Net Operating Revenue (X) 5.554.292.131.941.54
EV / EBITDA (X) 21.0518.4310.189.588.48
MarketCap / Net Operating Revenue (X) 5.764.352.242.101.65
Retention Ratios (%) 85.5577.3576.5276.860.00
Price / BV (X) 7.106.753.743.622.96
Price / Net Operating Revenue (X) 5.764.352.242.101.65
EarningsYield 0.040.030.050.050.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

RPG Life Sciences Ltd. is a Public Limited Listed company incorporated on 29/03/2007 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24232MH2007PLC169354 and registration number is 169354. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 653.43 Cr. and Equity Capital is Rs. 13.23 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsRPG House, Mumbai Maharashtra 400030Contact not found
Management
NamePosition Held
Mr. Harsh V GoenkaChairman
Mr. Ashok NairManaging Director
Mr. Rajat BhargavaNon Executive Director
Mr. Yugal SikriNon Executive Director
Ms. Vasundhara PatniNon Executive Director
Mr. Manoj K MaheshwariIndependent Director
Ms. Zahabiya KhorakiwalaIndependent Director
Mr. Bhaskar IyerIndependent Director
Mr. Sachin NandgaonkarIndependent Director
Ms. Radhika GuptaIndependent Director
Mr. Hiten KotakIndependent Director
Mr. Anil MataiIndependent Director

FAQ

What is the intrinsic value of RPG Life Sciences Ltd and is it undervalued?

As of 18 April 2026, RPG Life Sciences Ltd's intrinsic value is ₹1372.71, which is 26.91% lower than the current market price of ₹1,878.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (25.5 %), book value (₹335), dividend yield (1.07 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of RPG Life Sciences Ltd?

RPG Life Sciences Ltd is trading at ₹1,878.00 as of 18 April 2026, with a FY2026-2027 high of ₹2,725 and low of ₹1,731. The stock is currently near its 52-week low. Market cap stands at ₹3,105 Cr..

How does RPG Life Sciences Ltd's P/E ratio compare to its industry?

RPG Life Sciences Ltd has a P/E ratio of 29.6, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is RPG Life Sciences Ltd financially healthy?

Key indicators for RPG Life Sciences Ltd: ROCE of 32.8 % indicates efficient capital utilization; ROE of 25.5 % shows strong shareholder returns. Dividend yield is 1.07 %.

Is RPG Life Sciences Ltd profitable and how is the profit trend?

RPG Life Sciences Ltd reported a net profit of ₹183 Cr in Mar 2025 on revenue of ₹653 Cr. Compared to ₹51 Cr in Mar 2022, the net profit shows an improving trend.

Does RPG Life Sciences Ltd pay dividends?

RPG Life Sciences Ltd has a dividend yield of 1.07 % at the current price of ₹1,878.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in RPG Life Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports